Glecaprevir + pibrentasvir – November 2020

• Brand names:
  • Maviret®
• Pharmaceutical Company:
  • AbbVie Pty Ltd
• Condition/Indication: Chronic Hepatitis C infection
• Meeting Date: November 2020
• Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 870KB)
• Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 78KB)

Related Public Summary Documents

• Glecaprevir + pibrentasivir – December 2020